Comprehensive Genomic Profiling of Cancer Samples
Comprehensive genomic profiling (CGP) unlocks insight into cancer variants at the genetic level to advance precision oncology. Harnessing next-generation sequencing (NGS) technology, the Agilent SureSelect Cancer CGP assay enables genomic profiling of cancer samples with a panel of globally curated genes, for detection of key classes of somatic variants and immuno-oncology biomarkers. Watch this video to learn how the SureSelect Cancer CGP assay can help you efficiently and precisely assess cancer tumor samples.
Learn about the design and performance of the SureSelect Cancer CGP assay—a pan-cancer, hybrid-capture target enrichment NGS assay that provides a modular and flexible approach to tumor characterization. See how the assay enables CGP of solid tumors by targeting cancer-specific genes to detect key classes of somatic variants and includes automation and data analysis options.
Optimized with error-correcting molecular barcodes and minimal sample input, the SureSelect Cancer CGP assay provides a streamlined workflow for high-performance results and reproducible detection of key somatic variants and translocations from both DNA and RNA. View the pan-cancer performance results in the data sheet.
The SureSelect Cancer CGP assay utilizes Agilent SureSelect XT HS2 library preparation and target enrichment chemistry to empower your lab’s NGS workflow. The pan-cancer NGS panel detects somatic variants including:
In addition, the SureSelect Cancer CGP assay assesses immuno-oncology biomarkers such as:
To learn more, visit our SureSelect Cancer CGP assays product page.
For Research Use Only. Not for use in diagnostic procedures.
PR7001-1677
